OMEROS CORP (OMER) Stock News

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Mentions: NATL TMO PONY WKSP

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Mentions: PBM VRTX AEMD BPTH ...

OMER Stock Earnings: Omeros Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Omeros (NASDAQ:OMER) just reported results for the second quarter of 2024.Omero...

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

OMER Stock Earnings: Omeros Misses EPS for Q2 2024

OMER stock results show that Omeros missed analyst estimates for earnings per share the second quarter of 2024.

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation Reports Third Quarter 2024 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Omeros Corporation Reports Second Quarter 2024 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028